15th Nov 2013 11:44
LONDON (Alliance News) - GW Pharmaceuticals PLC said Friday that its Epidiolex childhood epilepsy treatment had been granted an orphan drug designation by the US Food and Drug Administration.
The orphan drug qualification means that the product has been designed specifically to tackle a rare disease that affects a small percentage of the population. This designation means that developers are entitled to a seven-year exclusive marketing period in the US for the product.
The Epidiolex treatment is for children with the rare Dravet syndrome, a genetic epilepsy condition that is drug resistant.
GW Pharmaceuticals is a biotechnology company focused on developing treatments using cannabinoids, derived from the cannabis plant.
Shares in GW were trading down 0.3% at 176.78 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L